Robert Z. Orlowski (@myeloma_doc) ranks #12 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 23 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: CASSIOPEIA, EXCALIBER-RRMM, CEPHEUS. CMS Open Payments lists $17,403 in 2025 general payments.
At a Glance
- 6 posts naming a trial since ASH 2025
- 4 trials discussed by name
- Multiple Myeloma: US #12, Global #14 · 23 physicians engaged
- Leading physician voice: #1 of 3 physicians on CASSIOPEIA; #2 of 8 physicians on CEPHEUS
- Presented at ASH 2025 in 2026
- CMS Open Payments lists $17,403 in 2025 general payments.
This Month
What Robert Z. Orlowski has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
Who Amplifies Robert Z. Orlowski
Physicians who reposted Robert Z. Orlowski’s trial posts most often since ASH 2025.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #12 | #14 | 58/100 | 23 | 33 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Robert Z. Orlowski presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASH 2025 · OralLINKER-MM4: upfront linvoseltamab (BCMA bispecific) in newly diagnosed myelomaSource: @HadidiSamer on X ↗
What Colleagues Are Saying About Robert Z. Orlowski
2026 posts by fellow physicians that mention @myeloma_doc, quoted word for word.
#ASH25 @AlfredChung11 updated AURIGA focused on MRD dynamics, including MRD resurgence ( ➖ ➡️➕). Similar to IMROZ data last year by @Myeloma_Doc ... MRD resurgence less common with continued CD38 pressure, even in HR. Another argument in favor of its inclusion in maintenance! https://t.co/MUGIVxxLRP
#ASH25 #mmsm @ASH_hematology Oral myeloma- LINKER-MM4 @Myeloma_Doc High rates of MRD negativity, stem cell yield was provided for those who harvested stem cells https://t.co/T77nlVz8yf
Trials Robert Z. Orlowski Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| CASSIOPEIA | 3 | #1 of 3 | Aug 17, 2026 |
| EXCALIBER-RRMM | 1 | #5 of 13 | Sep 27, 2026 |
| CEPHEUS | 1 | #2 of 8 | Sep 26, 2026 |
| MAIA | 1 | #4 of 5 | Aug 26, 2026 |
Robert Z. Orlowski on CASSIOPEIA
#Myeloma Paper of the Day: CASSIOPEIA subgroup analysis finds NDMM pts w/ SLIM criteria (who had lower R-ISS rates, better ECOG PS) do better (PFS 37.5 vs. 32.2 mos, p=0.003; OS 80.9 vs. 73.2 months, p<0.001) vs those w/ traditional CRAB features: https://t.co/YohXN8qndj. #mmsm https://t.co/1b2z53oSWz
#Myeloma Paper of the Day: Results from CASSIOPEIA trial suggest pts w/ cyclin D1 overexpression & t(11;14) exhibit slower response rates after induction & high-dose therapy in setting of triplet or quads but long-term prognosis remains favorable: https://t.co/Z0LsN47LDU. #mmsm https://t.co/wZIkwN2DVt
#Myeloma Paper of the Day: Transcriptomic profiling of CASSIOPEIA pts identified 5 subtypes & 3 risk categories w/ 72-month PFS rates of 70%/51%/27% & refined value of MRD by identifying high-risk pts in whom MRD was insufficient to predict outcome: https://t.co/d2NlUjUMtA. #mmsm https://t.co/b7lh7aAehr
Robert Z. Orlowski on EXCALIBER-RRMM
#Myeloma Paper of the Day: EXCALIBER-RRMM phase 3 of iberdomide/dara/dex vs dara/bortez/dex shows (median follow-up 15.7 mos) MRD- CR in 85 (41%) vs. 44 (21%); grade 3-4 AEs in 187 (92%) vs 143 (70%), neutropenia (84% vs 11%) & infxn (39% vs 22%): https://t.co/VQrAqPwxzU. #mmsm https://t.co/shkzgx2Cj7
Robert Z. Orlowski on CEPHEUS
#Myeloma Paper of the Day: Efficacy & safety in CEPHEUS TIE pts (DVRd, n=144; VRd, n=145) show MRD- (10-5) 60.4% (DVRd) vs 39.3% (VRd; P=.0004); sustained MRD- ≥12 mos (47.2% v 28.3; P=.0010), ≥24 (40.3% v 22.8; P=.0015); OS favors DVRd (HR 0.66): https://t.co/sscSA4UxXp. #mmsm https://t.co/mWwi1P3tmj
Robert Z. Orlowski on MAIA
#Myeloma Paper of the Day: MAIA final survival analysis shows median OS 90.3 mos w/ DRd vs 64.1 w/ Rd; estimated 7-yr OS rates 53.1% & 39.3%; median TTNT not reached for D-Rd versus 42.4 months for Rd; comparable rate of death due to adverse events: https://t.co/kTd3syjhQM. #mmsm https://t.co/s3yYB6hc1I
Robert Z. Orlowski’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
#Myeloma Paper of the Day: CAR-PRISM phase 2 trial of Ciltacabtagene autoleucel in high-risk smoldering myeloma finds all patients achieved MRD negativity 10-6 by 2 mos & have remained negative; CRS in 100%, non-ICANS neurologic toxicities in 35%: https://t.co/5unLUHp1R6. #mmsm https://t.co/4Y3vrcH2MH
#Myeloma Paper of the Day: Talquetamab + teclistamab in pts w/ drug-resistant true extramedullary myeloma show ORR 79%, PFS @ 12 mos was 61%, OS was 74%; common grade 3/4 AEs were heme in 76% & infection in 31%; 10 deaths (5 treatment, 5 infection): https://t.co/ouWZgWaKYH. #mmsm https://t.co/OJylESjwiu
The two FDA approved BCMA CAR T products for #myeloma (ide-cel & cilta-cel), and both have strengths & weaknesses. A third (anito-cel) may be approved by the end of 2026, while a GPRC5D-targeted CAR (arlo-cel) may be approved next year. No in vivo CARs have made it that far yet. https://t.co/0lt5GnHms1
Industry Payments
CMS Open Payments · 2025 general payments
$17,403 across 20 payments